BMS said it will launch Cobenfy within the next few weeks and has set a price of $1,850 per month for the medicine, which is considerably more than the current, largely generic array of ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

For most of the reviews here at Gadgets 360, we use the mobile in question as our primary phone for about a week or so before sharing our verdict with you. We realise this isn't perfect, since there ...

iOS 16 to Drop Support for iPhone 6s Series, First Generation iPhone SE, and Older iPads: Report ...